Abstract
Aims: The aim is to study the role of miR-675-5p coded by long non-coding RNA H19 in the development of Nasopharyngeal Cancer (NPC) and whether miR-675-5p regulates the invasion and metastasis of NPC through targeting SFN (14-3-3σ). The study further validated the relationship between H19, miR-675-5p and SFN in NPC and their relationship with the invasion and metastasis of NPC.
Methods: Western blot was used to detect the expression of 14-3-3σ protein in immortalized normal nasopharyngeal epithelial cells NP69 and different metastatic potential NPC cells, 6-10B and 5-8F. At the same time, to find out the relationship between 14-3-3σ protein and the expression of H19 and miR-675-5p, the expression of H19 and miR-675-5p in normal nasopharynx epithelial cells NP69 and varied nasopharyngeal carcinoma cells 6-10B and 5-8F were quantified by real-time PCR. MiR-675-5p mimic and inhibitor were transfected into NPC 6-10B to over-express and down-express miR-675-5p; miR-675-5p mimic negative control and inhibitor negative control were transfected into NPC 6-10B as control groups. The effect of over-expression and down-expression by miR-675-5p on the expression of 14-3-3σ protein was detected by Western blotting. The 3’-UTR segments of SFN, containing miR-675-5p binding sites were amplified by PCR and the luciferase activity in the transfected cells was assayed to detect whether SFN is the direct target of miR-675-5p. Transwell and scratch assays were used to verify the changes in NPC invasion and metastasis ability of mimics and inhibitors transfected with miR-675-5p.
Results: The expression of 14-3-3σ protein in normal nasopharynx epithelial cells NP69 is significantly higher than in varied nasopharyngeal carcinoma cells, 6-10B and 5-8F (P<0.05), and the 14-3-3σ protein levels in low-metastatic nasopharyngeal carcinoma cell 6-10B is higher than in high-metastatic nasopharyngeal carcinoma cell 5-8F. The expression of H19 and miR-675-5p are significantly higher in NPC cells than in NP69 cell (P<0.05). The expression of H19 and miR-675-5p in high-Metastatic nasopharyngeal carcinoma cell 5-8F was higher than in low-Metastatic nasopharyngeal carcinoma cell 6-10B. The expression of 14-3-3σ protein in miR-675-5p mimic cells was significantly lower than in mimic NC (negative control) group and blank control group. However, compared with the blank control group, mimic NC showed no significant difference in 14-3-3σ protein between the two groups. The miR-675-5p inhibitor group was significantly higher than the inhibitor NC group and the blank control group (p<0.05), but there was no significant difference in the expression of 14-3-3σ protein in the inhibitor NC group and the blank control group (p>0.05). Dual-luciferase reporter assay system shows the 3’-UTR segments of SFN containing miR-675-5p binding sites. SFN was the target gene of miR-675-5p.
Conclusion: 14-3-3σ is downregulated in NPC and is involved in the development of NPC. H19 and miR- 675-5p are upregulated in NPC, which is related to the development of NPC. The over-expression of miR- 675-5p inhibits the expression of 14-3-3σ protein. SFN is the target gene of miR-675-5p. MiR-675-5p targets SFN, downregulates its protein expression and promotes the invasion and metastasis of NPC.
Keywords: NPC, miR-675-5p, 14-3-3σ, invasion, metastasis, nasalpharyngeal, cancer cells.
[http://dx.doi.org/10.1186/s40880-018-0338-4] [PMID: 30577735]
[http://dx.doi.org/10.1016/j.clon.2012.10.006] [PMID: 23337060]
[http://dx.doi.org/10.1186/s12859-018-2536-0] [PMID: 30577741]
[http://dx.doi.org/10.1038/nature12946] [PMID: 24476892]
[PMID: 21187508]
[http://dx.doi.org/10.3892/ol.2014.2676] [PMID: 25435977]
[http://dx.doi.org/10.1038/onc.2010.550] [PMID: 21132010]
[http://dx.doi.org/10.1016/j.biocel.2009.10.001] [PMID: 19828132]
[http://dx.doi.org/10.1158/1078-0432.CCR-07-1215] [PMID: 18223218]
[http://dx.doi.org/10.1002/jcb.22051] [PMID: 19160382]
[http://dx.doi.org/10.1186/s12943-015-0458-2] [PMID: 26536864]
[http://dx.doi.org/10.18632/oncotarget.4154] [PMID: 26068968]
[http://dx.doi.org/10.1159/000480028] [PMID: 28848149]
[PMID: 30280776]
[http://dx.doi.org/10.1080/15384101.2018.1482137] [PMID: 29950144]
[http://dx.doi.org/10.2147/OTT.S149908] [PMID: 29403287]
[http://dx.doi.org/10.1002/jcb.27669] [PMID: 30474270]
[http://dx.doi.org/10.3892/ol.2015.3165] [PMID: 26171017]
[http://dx.doi.org/10.1016/j.molcel.2013.08.027] [PMID: 24055342]
[http://dx.doi.org/10.3390/ijms14024298] [PMID: 23429271]
[http://dx.doi.org/10.1261/rna.351707] [PMID: 17237358]
[http://dx.doi.org/10.7150/jca.21347] [PMID: 29344285]
[http://dx.doi.org/10.3892/ol.2018.8788] [PMID: 30061949]
[http://dx.doi.org/10.3892/mmr.2018.8894] [PMID: 29693120]
[PMID: 28861150]
[http://dx.doi.org/10.2147/OTT.S135664] [PMID: 28652762]
[http://dx.doi.org/10.1139/bcb-2016-0237] [PMID: 28525724]
[http://dx.doi.org/10.2147/OTT.S126781] [PMID: 28228659]
[PMID: 29798333]
[http://dx.doi.org/10.18632/oncotarget.10761] [PMID: 27458165]
[http://dx.doi.org/10.18632/oncotarget.6504] [PMID: 26655091]
[http://dx.doi.org/10.1002/cbf.3152] [PMID: 26559153]
[http://dx.doi.org/10.3892/ijmm.2015.2245] [PMID: 26081980]
[http://dx.doi.org/10.1186/s12885-015-1464-x] [PMID: 26055874]
[http://dx.doi.org/10.12659/MSM.898110] [PMID: 27840403]
[http://dx.doi.org/10.1002/cam4.863] [PMID: 27774777]
[http://dx.doi.org/10.1002/jbt.21827] [PMID: 27501413]
[http://dx.doi.org/10.1038/cddis.2016.64] [PMID: 27010857]
[http://dx.doi.org/10.3390/ijms19092810]
[http://dx.doi.org/10.1002/hed.25544] [PMID: 30548946]
[PMID: 26623562]
[http://dx.doi.org/10.1016/j.humpath.2017.09.006] [PMID: 28970140]
[http://dx.doi.org/10.18632/oncotarget.4976] [PMID: 26353930]
[PMID: 26379923]
[http://dx.doi.org/10.1016/j.bbrc.2013.12.126] [PMID: 24388988]
[http://dx.doi.org/10.1007/s00109-018-1687-9] [PMID: 30140938]
[http://dx.doi.org/10.1186/s12943-015-0342-0] [PMID: 25889562]
[http://dx.doi.org/10.1002/stem.2225] [PMID: 26417995]
[http://dx.doi.org/10.1111/febs.12902] [PMID: 24988946]